MarketPulse
M

$MDGL

4 articles found
3 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Madrigal Pharma to Report Q1 2026 Results as Rezdiffra Ramps Up Commercial Launch

Madrigal Pharmaceuticals reports Q1 2026 results May 6, revealing early commercial performance of FDA/EMA-approved MASH treatment Rezdiffra following recent regulatory clearances.
MDGLfinancial resultsFDA approval
BenzingaBenzinga··Usa News Group

$578B Regenerative Medicine Market Faces Manufacturing Crisis as Avaí Bio Pioneers Cell Banking Solution

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.
PRMEIOVAAVAIMDGLDNLIFDA approvalregenerative medicine
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Two Biotech Stocks Poised to Outpace Summit Therapeutics Amid FDA Uncertainty

Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.
AXSMMDGLSMMTregulatory riskFDA approval
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.
ARGXAPLSMDGLINSMinstitutional investmentbiotech investment